What is ClearPoint Neuro's market cap?

ClearPoint Neuro (CLPT) has a market capitalization of $536.2M and trades on NASDAQ.

What is ClearPoint Neuro's revenue and profitability?

ClearPoint Neuro generated $40.6M in trailing twelve-month revenue with a net loss of $29.1M, representing a net margin of -71.6%. Gross margin stands at 62.3%, with free cash flow of -$26.7M. These figures are based on the Q1 2026 filing.

Who are ClearPoint Neuro's competitors?

ClearPoint Neuro's key competitors include Medtronic plc, Integra LifeSciences Holdings Corporation, Boston Scientific, and others. These companies compete in similar markets and product categories.

Who does ClearPoint Neuro partner with?

ClearPoint Neuro's notable partners include Clinical Laserthermia Systems AB, Philips, PTC Therapeutics, Inc., and others.

What subsidiaries does ClearPoint Neuro have?

ClearPoint Neuro's subsidiaries include IRRAS Holdings, Inc..

Where is ClearPoint Neuro headquartered?

ClearPoint Neuro is headquartered in United States of America and employs approximately 107 people. It has been publicly traded since 2012.

ClearPoint Neuro

CLPT

ClearPoint Neuro is a commercial-stage medical device company specializing in integrated systems for minimally invasive neurosurgical procedures and neurocritical care.

Market cap

$536.21M+58.6%

Revenue$40.6M+26.0%

Net income-$29.1M-39.8%

Free cash flow-$26.7M-127%

EPS (diluted)-$1.01-32.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$12.1MBeat by $161.3K EPS-$0.32Miss by $0.04

Read the full report

Next report

Aug 11, 2026 (in a month)

Revenue estimate$12.7M

EPS estimate-$0.27

Financials

Q1 2026

Income statement

See full

Revenue$12.1M+42.9%

Gross profit$7.8M+51.1%

Operating income-$8.5M-37.6%

Net income-$9.6M-58.5%

EPS (diluted)-$0.32-45.5%

Balance sheet

See full

Cash & equivalents$36.5M+195%

Total debt$63.6M+1,750%

Total equity$18.8M-5.7%

Total assets$93.4M+211%

Cash flow

See full

Operating cash flow-$8.0M-29.1%

CapEx$645.0K+252%

Free cash flow-$8.6M-35.5%

Valuation & ratios

Valuation

See full

Market cap$536.21M+58.6%

Enterprise value$563.29M+72.1%

P/S13.2×+3.3×

Profitability

See full

Gross margin62.3%+1.1pp

Operating margin-65.2%-1.9pp

Net margin-71.6%+8.8pp

FCF margin-65.7%+269pp

Returns & leverage

See full

Return on equity-149.7%+4,074pp

Debt / equity3.4×+3.2×

Current ratio5.8×+2.3×

Segments

By product

See full

Neurosurgery Navigation And Therapy$5.9M+79.6%

Neurosurgery Navigation And Therapy Disposable Products$5.9M+79.6%

Biologics And Drug Delivery$4.8M+2.5%

Biologics And Drug Delivery Services And License Fees$2.9M+0.1%

Biologics And Drug Delivery Disposable Products$1.9M+6.5%

Competitors

By market cap

Abbott$164.43B-29.3%

Stryker$125.40B-16.4%

Medtronic$105.46B-6.1%

Boston Scientific$66.9B-56.5%

Zimmer Biomet Holdings$17.3B-5.7%

IAR

Integra LifeSciences$1.4B+44.4%

ClearPoint Neuro$536.2M+60.8%

Orthofix Medical Inc.$464.0M+10.5%

By revenue growth

ClearPoint Neuro+26.0%

Boston Scientific+17.4%

Zimmer Biomet Holdings+9.2%

Stryker+8.8%

Medtronic+8.4%

Abbott+6.6%

Orthofix Medical Inc.+2.6%

IAR

Integra LifeSciences+1.2%

By net margin

Boston Scientific17.26%+5.7pp

Abbott13.91%-18.0pp

Stryker13.21%+0.9pp

Medtronic13.2%-0.7pp

Zimmer Biomet Holdings9.05%-2.8pp

Orthofix Medical Inc.-7.27%+10.5pp

IAR

Integra LifeSciences-30.15%-27.0pp

ClearPoint Neuro-71.57%-7.1pp

Profile

ClearPoint Neuro is a commercial-stage medical device company specializing in integrated systems for minimally invasive neurosurgical procedures and neurocritical care. The company provides a navigation platform for real-time MRI-guided and operating room interventions, alongside a biologics and drug delivery business that supports pharmaceutical partners in developing gene and cell therapies. Its core value proposition lies in enhancing the precision of intracranial drug delivery and fluid management for complex neurological conditions.

Competitive position

The company is a leader in MRI-guided neuro-navigation and is expanding its footprint into the operating room and neurocritical care markets through strategic acquisitions and exclusive licensing.

GeographiesUnited States, European Union, United Kingdom, Brazil, Canada, China, Japan

Customer segmentsAcute care hospitals, Pharmaceutical R&D, Clinical research organizations

Business modelRazor-and-blade, Capital equipment sales, Professional services, Licensing

SuppliersSingle-source component suppliers, Contract manufacturers, MRI scanner manufacturers, Software technology licensors

CustomersTertiary care hospitals, Neurosurgical departments, Gene therapy developers, Intensive care units

CountryUnited States of America

Listed2012

Employees107.0

CEOJoseph Michael Burnett

SectorHealthcare

IndustryMedical - Devices

Websiteclearpointneuro.com

FilingsSEC EDGAR

Ask your AI about ClearPoint Neuro.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ClearPoint Neuro's market cap?: ClearPoint Neuro (CLPT) has a market capitalization of $536.2M and trades on NASDAQ.
What is ClearPoint Neuro's revenue and profitability?: ClearPoint Neuro generated $40.6M in trailing twelve-month revenue with a net loss of $29.1M, representing a net margin of -71.6%. Gross margin stands at 62.3%, with free cash flow of -$26.7M. These figures are based on the Q1 2026 filing.
Who are ClearPoint Neuro's competitors?: ClearPoint Neuro's key competitors include Medtronic plc, Integra LifeSciences Holdings Corporation, Boston Scientific, and others. These companies compete in similar markets and product categories.
Who does ClearPoint Neuro partner with?: ClearPoint Neuro's notable partners include Clinical Laserthermia Systems AB, Philips, PTC Therapeutics, Inc., and others.
What subsidiaries does ClearPoint Neuro have?: ClearPoint Neuro's subsidiaries include IRRAS Holdings, Inc..
Where is ClearPoint Neuro headquartered?: ClearPoint Neuro is headquartered in United States of America and employs approximately 107 people. It has been publicly traded since 2012.